Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ, Wei AH. Loo S, et al. Among authors: latimer m. Blood. 2023 Dec 7;142(23):1960-1971. doi: 10.1182/blood.2023020301. Blood. 2023. PMID: 37647654 Free PMC article. Clinical Trial.
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
McCaughan G, Di Ciaccio P, Ananda-Rajah M, Gilroy N, MacIntyre R, Teh B, Weinkove R, Curnow J, Szer J, Enjeti AK, Ross DM, Mulligan S, Trotman J, Dickinson M, Quach H, Choi P, Polizzotto MN, Tam CS, Ho PJ, Ku M, Gregory G, Gangatharan S, Hapgood G, Cochrane T, Cheah C, Gibbs S, Wei A, Johnston A, Greenwood M, Prince HM, Latimer M, Berkahn L, Wight J, Armytage T, Hamad N. McCaughan G, et al. Among authors: latimer m. Intern Med J. 2021 May;51(5):763-768. doi: 10.1111/imj.15247. Intern Med J. 2021. PMID: 34047035 Free PMC article.
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Perram J, et al. Among authors: latimer m. Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978. Intern Med J. 2023. PMID: 36371767 Free PMC article.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH; Australasian Leukaemia and Lymphoma Group (ALLG). Tiong IS, et al. Among authors: latimer m. Blood Cancer J. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x. Blood Cancer J. 2024. PMID: 38531863 Free PMC article.
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Campbell A, Teh B, Mulligan S, Ross DM, Weinkove R, Gilroy N, Gangatharan S, Prince HM, Szer J, Trotman J, Lane S, Dickinson M, Quach H, Enjeti AK, Ku M, Gregory G, Hapgood G, Ho PJ, Cochrane T, Cheah C, Greenwood M, Latimer M, Berkahn L, Wight J, Armytage T, Diamond P, Tam CS, Hamad N. Campbell A, et al. Among authors: latimer m. Intern Med J. 2024 Feb;54(2):328-336. doi: 10.1111/imj.16303. Epub 2023 Dec 25. Intern Med J. 2024. PMID: 38146232
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
186 results